I would like to thank the substantial shareholder group for doing such a fantastic job considering the circumstances. The fact that the founders of the science Dr Alice Cavanagh and Dr Halle Morton endorse the group and the board changes says it all. (have posted the endorsement below).
4 new directors Dr David Young , Dr Declan Doogan, Dr Gregory Bailey MD, Dr Wolfgang Berthold PhD have offered to serve on the board. The credentials of these candidates are exceptional. I am excited about the companys future with these developments.
ENDORSEMENT BY CBIO’S FOUNDING SCIENTIFIC DIRECTORS “As the inventors of the original patent on Chaperonin 10, the protein on which XToll® is based, we were proud to become CBio Ltd’s founding Scientific Directors shortly after the Company was formed in 2000 to develop and commercialise the drug. “Our research began in the early 1970s at the University of Queensland and the University, through its commercial arm, Uniquest Ltd, is still a major shareholder in CBio. “We are confident in the science and believe that because of its strong safety profile and efficacy at the right dose, XToll® eventually will benefit millions of people throughout the world who suffer from rheumatoid arthritis and other auto-immune diseases such as MS, lupus and psoriasis. “However, while we are pleased that progress has been made, we are frustrated that more than 10 years have elapsed and it seems that the drug is still years away from getting to the market. “We support the campaign by the Substantial Shareholder Group to restructure and rejuvenate the CBio Board and will be voting our shareholdings for change. “We encourage all shareholders to vote FOR the 6 resolutions.” Dr Halle Morton Dr Alice Cavanagh
CBZ Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held